Current Report Filing (8-k)
July 25 2019 - 5:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
June 30, 2019
Natus Medical Incorporated
(Exact name of registrant as specified in its charter)
000-33001
(Commission File Number)
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
77-0154833
|
|
(State or other jurisdiction
of Incorporation)
|
|
(I.R.S. Employer
Identification No.)
|
6701 Koll Center Parkway, Suite 120
Pleasanton, CA 94566
(Address of principal executive offices)
925-223-6700
(Registrant’s telephone number, including area code) (Zip Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value per share
|
NTUS
|
The Nasdaq Stock Market LLC
(The Nasdaq Global Market)
|
|
|
|
|
|
|
Item 2.02.
|
Results of Operations and Financial Condition
|
On
July 25, 2019
, Natus Medical Incorporated (the “Company”) is issuing a press release and holding a conference call regarding its financial results for the
second
quarter ended
June 30, 2019
and other financial information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
|
|
|
|
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
|
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release dated July 25, 2019 describing the Company's results for its second quarter ended June 30, 2019 and other financial information.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NATUS MEDICAL INCORPORATED
(Registrant)
|
|
|
|
|
|
|
Dated: July 25, 2019
|
|
|
|
By:
|
/s/ B. Drew Davies
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Exhibit Index
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Nov 2024 to Dec 2024
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Dec 2023 to Dec 2024
